|
Commerce ministry to facilitate industry connect with regulators on December 17 to boost pharma exports
|
|
Shardul Nautiyal, Mumbai
December 16 , 2025
|
|
|
In order to explore opportunities to further strengthen India’s pharmaceutical exports, Union ministry of commerce through the Pharmaceuticals Export Promotion Council of India (Pharmexcil) will bring together regulatory authorities and industry leaders on a common platform in Chandigarh on December 17, 2025.
The event, which is part of the Chintan Shivir on Indian pharmaceutical industry, will facilitate direct interaction between the industry and policymakers. This will also help in bridging the communication gap towards addressing regulatory and policy challenges in the pharma exports and pharma sector.
As part of industry interaction, senior government officials, regulatory authorities, industry leaders, policy experts, and CEOs from leading pharmaceutical companies will discuss important areas of concern in the pharmaceutical sector, imports and exports.
The key sessions will start at 3 pm and conclude at 7 pm on December 17, 2025 at The Lalit, Rajiv Gandhi IT Park, Near DLF Commercial Complex, Chandigarh.
Topics of discussion will include with Session One on Antimicrobial Resistance (AMR) landscape in India: Consequences, Complexities, and Remedial Pathways, Session Two on Skill Development Initiatives of the Life Sciences Sector Skill Development Council (LSSSDC), Session Three on the Directorate General of Foreign Trade (DGFT) Workshop on Emerging Developments in Foreign Trade Policy (FTP), Session Four on overview of the evolving GST regime: policy developments and sectoral implications and conclude with industry interaction with key stakeholders.
Member companies of Pharmexcil have also been urged to provide their challenges and suggestions to make the sessions more impactful and purpose driven.
India is actively seeking to lower dependence on the US market due to tariff risks. There is also and increasing focus on Africa, Latin America, and Southeast Asia, and promoting finished goods exports to China to address the API trade deficit.
India's new FTP emphasizes e-governance, automated approvals (like Advance Authorisation), and digital trade, making compliance easier.
The DGFT launched a Global Tariff and Trade Helpdesk for pharma exporters to address issues like tariff escalations and regulatory hurdles in real-time, with Pharmexcil acting as a liaison.
Other encouraging scenario is that Governments is offering R&D subsidies and streamlined approvals to boost domestic production and competitiveness. There is an increasing shift towards refunding embedded taxes (like RoDTEP) to reduce exporter costs. Tailored incentives and smoother processes are helping Indian firms compete globally, especially in generics, and building capabilities in biologics.
Market opportunities are being explored by Indian pharma exporters with focus on semi-regulated markets like Africa and South East Asia. There are new product launches in generics, biologics and novel formulations, which are creating growth avenues. Diversifying markets and strengthening local manufacturing is also reducing vulnerability to trade wars or sudden policy changes in major markets.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|